CVS Caremark’s Recent Cardiovascular Study Examines Underutilized Results

CVS Caremark’s new study, published in the November issue of the AHA’s journal Circulation: Cardiovascular Quality and Outcomes, examines genetic testing in cardiovascular treatment and what is being done with its patients. According to the study, a significant amount of patients were recognized as poor metabolizers of the blood thinner clopidogrel, however only a small amount of those patients took action from the results. This leaves a large, open opportunity to provide physicians with the knowledge needed to understand and correct their patient’s medications.

¬†“While there is significant uncertainty about how clinician’s should respond to the results of genetic testing for anti platelet drugs, this study clearly¬†shows that patients and their doctors need more guidance and education about how best to apply these results to improve patient incomes,” says Niteesh K. Choudhry, MD, PhD, associate physician, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, associate professor, Harvard Medical School and the study’s senior investigator.

by Content_Management
This entry was posted in Interesting Reads. Bookmark the permalink.

Comments are closed.